Valmor 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (1 x 10: ৳ 450.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Square pharmaceuticals plc |
| Also available as |
Indications
- To reduce risk of cardiovascular death
- For hospitalization for heart failure
- For chronic heart failure (NYHA Class ll-IV)
- For treatment of symptomatic heart failure in pediatric patients
- Usually administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor, sacubitril
- Contains angiotensin receptor blocker, valsartan
- Inhibits neprilysin (NEP) via LBQ657
- Blocks the angiotensin II type-1 (AT1) receptor via valsartan
- Increases levels of peptides degraded by neprilysin
Dosage & Administration
- Recommended starting dose for adults: 49/51 mg orally twice daily
- Double the dose to target maintenance dose after 2-4 weeks
- Pediatric patients aged one year and older: refer to Table 1 for recommended dose
- Adjust pediatric patient doses every 2 weeks
Interaction
- Should not be used with an ACEi
- Avoid use with an ARB
- May increase serum potassium level
- Risk of renal impairment may be increased with NSAIDs
- Increased risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year
- No relevant pharmacokinetic differences in elderly patients
- No dose adjustment required for mild hepatic impairment
- Not recommended in severe hepatic impairment
- No dose adjustment required in mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium periodically
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences in elderly patients
- Starting dose adjustment recommended for severe renal impairment
- Starting dose adjustment recommended for moderate hepatic impairment
- Not recommended in severe hepatic impairment
Overdose Effects
- Limited data available
- Hypotension is most likely result
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children